KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Assets: 2013-2025

Historic Other Non-Current Assets for Travere Therapeutics (TVTX) over the last 11 years, with Sep 2025 value amounting to $10.3 million.

  • Travere Therapeutics' Other Non-Current Assets fell 40.11% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year decrease of 40.11%. This contributed to the annual value of $18.2 million for FY2024, which is 70.36% up from last year.
  • According to the latest figures from Q3 2025, Travere Therapeutics' Other Non-Current Assets is $10.3 million, which was down 47.82% from $19.6 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Other Non-Current Assets ranged from a high of $48.3 million in Q4 2022 and a low of $10.3 million during Q3 2025.
  • In the last 3 years, Travere Therapeutics' Other Non-Current Assets had a median value of $16.9 million in 2024 and averaged $15.1 million.
  • In the last 5 years, Travere Therapeutics' Other Non-Current Assets skyrocketed by 414.92% in 2021 and then crashed by 77.95% in 2023.
  • Travere Therapeutics' Other Non-Current Assets (Quarterly) stood at $11.1 million in 2021, then soared by 336.73% to $48.3 million in 2022, then slumped by 77.95% to $10.7 million in 2023, then soared by 70.36% to $18.2 million in 2024, then plummeted by 40.11% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q3 2025, $19.6 million for Q2 2025, and $18.7 million during Q1 2025.